Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 9 | 2023 | 281 | 1.410 |
Why?
|
| Skin Neoplasms | 6 | 2022 | 349 | 0.730 |
Why?
|
| Indoles | 1 | 2013 | 84 | 0.470 |
Why?
|
| Sulfonamides | 1 | 2013 | 115 | 0.460 |
Why?
|
| Neoplasms | 7 | 2020 | 1058 | 0.420 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 533 | 0.410 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 125 | 0.360 |
Why?
|
| Immunotherapy | 2 | 2020 | 219 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 284 | 0.330 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2013 | 50 | 0.230 |
Why?
|
| T-Box Domain Proteins | 2 | 2012 | 36 | 0.220 |
Why?
|
| Campylobacter Infections | 1 | 2020 | 4 | 0.210 |
Why?
|
| Oxadiazoles | 1 | 2020 | 4 | 0.200 |
Why?
|
| Benzimidazoles | 1 | 2020 | 49 | 0.190 |
Why?
|
| Hydroxamic Acids | 2 | 2009 | 23 | 0.180 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 28 | 0.180 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 27 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 2 | 2010 | 48 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 3 | 2015 | 740 | 0.180 |
Why?
|
| Colitis | 1 | 2019 | 64 | 0.170 |
Why?
|
| ErbB Receptors | 2 | 2010 | 98 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 96 | 0.170 |
Why?
|
| Bacteria | 1 | 2020 | 236 | 0.170 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 313 | 0.160 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 199 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 372 | 0.150 |
Why?
|
| Diet | 1 | 2020 | 603 | 0.140 |
Why?
|
| Ipilimumab | 3 | 2022 | 11 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 46 | 0.140 |
Why?
|
| Humans | 18 | 2023 | 49658 | 0.130 |
Why?
|
| POU Domain Factors | 1 | 2012 | 2 | 0.120 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 17 | 0.120 |
Why?
|
| Cadherins | 1 | 2012 | 66 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2013 | 301 | 0.110 |
Why?
|
| Drug Design | 1 | 2013 | 139 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2012 | 280 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 231 | 0.100 |
Why?
|
| Quinazolines | 1 | 2010 | 14 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 378 | 0.100 |
Why?
|
| Retinoblastoma Protein | 1 | 2010 | 34 | 0.100 |
Why?
|
| Aged | 8 | 2020 | 10869 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 459 | 0.090 |
Why?
|
| Europe | 2 | 2023 | 145 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 3 | 2020 | 38 | 0.090 |
Why?
|
| Glycine | 1 | 2009 | 39 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 137 | 0.090 |
Why?
|
| Aminopeptidases | 1 | 2009 | 27 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 26 | 0.090 |
Why?
|
| Middle Aged | 8 | 2020 | 13448 | 0.090 |
Why?
|
| Adult | 8 | 2020 | 13328 | 0.090 |
Why?
|
| Disease Progression | 3 | 2020 | 718 | 0.090 |
Why?
|
| United Kingdom | 2 | 2020 | 54 | 0.090 |
Why?
|
| Prognosis | 3 | 2019 | 1251 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 65 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 31 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2012 | 2689 | 0.070 |
Why?
|
| Male | 8 | 2020 | 23131 | 0.070 |
Why?
|
| Female | 8 | 2020 | 26332 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2012 | 821 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2022 | 11 | 0.060 |
Why?
|
| Chemokine CCL8 | 1 | 2022 | 6 | 0.060 |
Why?
|
| Animals | 3 | 2020 | 17733 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4220 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1935 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 97 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 199 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2023 | 123 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2022 | 275 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2020 | 11 | 0.050 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2020 | 4 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 32 | 0.050 |
Why?
|
| Prodrugs | 1 | 2020 | 29 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 153 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2020 | 50 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2020 | 110 | 0.050 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 118 | 0.050 |
Why?
|
| Cetuximab | 1 | 2018 | 9 | 0.050 |
Why?
|
| Platinum | 1 | 2018 | 16 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 1249 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 225 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 209 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 359 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 1312 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 178 | 0.040 |
Why?
|
| Recurrence | 1 | 2018 | 496 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 173 | 0.040 |
Why?
|
| Protein Binding | 2 | 2012 | 1475 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 981 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2015 | 46 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 602 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 3888 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 473 | 0.030 |
Why?
|
| PAX3 Transcription Factor | 1 | 2012 | 14 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 46 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 59 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2008 | 2064 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2012 | 215 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 2520 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2012 | 89 | 0.030 |
Why?
|
| Melanocytes | 1 | 2012 | 65 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 157 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 448 | 0.030 |
Why?
|
| Cell Movement | 1 | 2012 | 386 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 68 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 250 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 150 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 621 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 61 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 106 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 623 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 341 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 58 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 885 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2010 | 309 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2017 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2007 | 23 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 790 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2007 | 46 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 729 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 534 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 16 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1500 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 656 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1886 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 110 | 0.020 |
Why?
|
| DNA | 1 | 2010 | 695 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 1919 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 4517 | 0.020 |
Why?
|
| Histones | 1 | 2008 | 430 | 0.020 |
Why?
|
| Insulin | 1 | 2007 | 658 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 9096 | 0.010 |
Why?
|